Drug Approval | March 23, 2024
Zydus receives tentative approval from USFDA for Letermovir Tablets
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
The event witnessed a historic journey of Thalassemics India gracing the theme “LAKSH”
Women of all ages will get round-the-clock access to comprehensive treatment
Acquisition expands Merck’s growing hematology portfolio
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Prime Minister said that it is a huge day for health in Gujarat and congratulated everyone associated with these projects for completing them on time.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
